State University of Buffalo (New York), and Cyclerion Therapeutics, has identified a promising approach for treating hereditary peripheral neuropathies, specifically Charcot Marie Tooth disease ...
Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send the pain signals like other analgesics, this ...
A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...
In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological disorders increased significantly ...
Scientists have designed a groundbreaking painkiller that activates solely at chronic pain sites, offering targeted, ...
He recently released a groundbreaking new book titled “A Patient’s Guide to Treating Peripheral Neuropathy.” This comprehensive guide is designed to empower individuals living with ...
Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...
People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study examined the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback